<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 56 patients were diagnosed as primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) at Chang Gung Memorial Hospital, Kaohsiung from April 1986 to December 1991 </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 65 years with an equal sex ratio </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients presented with <z:hpo ids='HP_0001903'>anemia</z:hpo> and 52% with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The overall median survival for the entire group was 7 months, in which the <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CMMoL) was 7 months, and 4 months for each of the <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) or the <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), however, the median survival had not been reached at 27 months for <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and at 33 months for <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Low-does arabinosyl <z:chebi fb="1" ids="16040">cytosine</z:chebi> (Ara-C) was administered in 9 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, but no survival benefit was noted </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e>, especially <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, was the most common cause of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In 61 febrile episodes with clinically suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 10 (17%) were documented to associate with <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Twelve patients (7 RAEB, 4 RAEB-T, and 1 CMMoL) evolved to <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), the median interval from diagnosis to evolution was 4.8 months </plain></SENT>
<SENT sid="8" pm="."><plain>This series indicates that only two groups of FAB subtypes could be clearly separated in terms of morphological findings and clinical outcome; RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> constitute a good prognostic group, whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, CMMoL, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> constitute a poor prognostic group </plain></SENT>
</text></document>